| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -177,440 | -110,396 |
| Depreciation and amortization | 2,564 | 1,740 |
| Amortization and premium of marketable securities, net | 4,973 | 3,955 |
| Loss on sale or disposal of assets | -12 | -6 |
| Stock-based compensation expense | 27,308 | 18,507 |
| Accounts and other receivables | -610 | -610 |
| Prepaid and other current assets | -235 | -3,020 |
| Other assets | -383 | -447 |
| Accounts payable and accrued expenses | 6,430 | -6,632 |
| Other liabilities | -2,134 | -1,724 |
| Net cash used in operating activities | -147,005 | -98,377 |
| Sales and maturities of marketable securities | 484,788 | 367,873 |
| Purchases of marketable securities | 329,708 | 274,080 |
| Acquisition of property and equipment | 1,433 | 993 |
| Net cash provided by (used in) investing activities | 153,647 | 92,800 |
| Proceeds from issuance of stock from employee benefit plans | 1,039 | 265 |
| Net cash provided by financing activities | 1,039 | 265 |
| Net increase in cash and cash equivalents | 7,681 | -5,312 |
| Cash and cash equivalents at beginning of period | 28,356 | - |
| Cash and cash equivalents at end of period | 36,037 | - |
Celldex Therapeutics, Inc. (CLDX)
Celldex Therapeutics, Inc. (CLDX)